Skip to main content
SpringerLink
Log in

Postoperative Adjuvant Therapy for Cervical Cancer

  • Chapter
  • First Online:
Recent Topics on Prevention, Diagnosis, and Clinical Management of Cervical Cancer

Part of the book series: Comprehensive Gynecology and Obstetrics ((CGO))

  • 70 Accesses

Abstract

Treatment for most patients with early-stage cervical cancer involves radical hysterectomy and pelvic lymph node dissection. Indications for postoperative adjuvant therapy are determined by evaluating prognostic risk factors for recurrence in each individual case. Several clinicopathological factors, such as tumor size, lymphovascular space involvement, deep stromal invasion, parametrial involvement, and lymph node metastasis, have been identified as having prognostic significance in early-stage cervical cancer. However, these indicators remain controversial because there is substantial heterogeneity among patients after radical hysterectomy and lymphadenectomy and it is difficult to define clear risk groups. There is thus an unmet need to develop more accurate criteria to define risk groups and treat accordingly.

According to the currently available evidence, there remains the question of whether CCRT-P delivers a survival benefit superior to radiotherapy (RT) alone for patients with high-risk factors after radical surgery. In addition to this issue, patients with high-risk factors have a high incidence of distant metastasis, for whom systemic chemotherapy might be the key to improving overall survival.

Results from the pivotal study GOG092, that investigated the role of RT alone for patients with intermediate-risk factors after hysterectomy, also failed to resolve this issue. That trial did not show that postoperative RT significantly improved overall survival relative to no further treatment, even though a reduction in the risk of recurrence after RT was documented. However, the study did indicate that patients allocated to the RT group experienced an increase in severe toxicities compared with the NFT group. This could be why many physicians are reluctant to treat patients using this approach, although the guidelines recommend RT for patients with intermediate-risk factors.

Further improvement in adjuvant therapy will depend on more robust definition of prognostic risk factors, better patient selection, and refinements in both local and systemic therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191-e 203.

    Article  Google Scholar 

  2. Ginsburg O, Bray M, Coleman MP, et al. The global burden of women’ cancers: a grand challenge in global health. Lancet. 2017;389:847–60.

    Article  PubMed  Google Scholar 

  3. Benedet JL, Odicino F, Maisonneuve P, et al. Carcinoma of the cervix uteri. J Epidemiol Biostat. 2001;6:7–43.

    CAS  PubMed  Google Scholar 

  4. Ebina Y, Mikami M, Nagase S, et al. Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. Int J Clin Oncol. 2019;24:1–19.

    Article  CAS  PubMed  Google Scholar 

  5. Fuller AF Jr, Elliott N, Kosloff C, et al. Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix. Gynecol Oncol. 1989;33:34–9.

    Article  PubMed  Google Scholar 

  6. Piver MS, Chung WS. Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma. Obstet Gynecol. 1975;46:507–10.

    CAS  PubMed  Google Scholar 

  7. Sevin BU, Lu Y, Bloch DA, et al. Surgically defined prognostic parameters in patients with early cervical carcinoma. A multivariate survival tree analysis. Cancer. 1996;78:1438–46.

    Article  CAS  PubMed  Google Scholar 

  8. Snijders-Keilholz A, Hellebrekers BW, Zwinderman AH, et al. Adjuvant radiotherapy following radical hysterectomy for patients with early-stage cervical carcinoma (1984–1996). Radiother Oncol. 1999;51:161–7.

    Article  CAS  PubMed  Google Scholar 

  9. Soisson AP, Soper JT, Clarke-Pearson DL, et al. Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer. Gynecol Oncol. 1990;37:390–5.

    Article  CAS  PubMed  Google Scholar 

  10. Stock RG, Chen AS, Flickinger JC, et al. Node-positive cervical cancer: impact of pelvic irradiation and patterns of failure. Int J Radiat Oncol Biol Phys. 1995;31:31–6.

    Article  CAS  PubMed  Google Scholar 

  11. Peters WA III, Liu PY, Barrett RJ II, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of cervix. J Clin Oncol. 2000;18:1606–13.

    Article  CAS  PubMed  Google Scholar 

  12. Lahousen M, Haas J, Pickel H, et al. Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: a randomized, prospective, multicenter trial. Gynecol Oncol. 1999;73:196–201.

    Article  CAS  PubMed  Google Scholar 

  13. Rose PG. Advances in the management of cervical cancer. J Reprod Med. 2000;45:971–8.

    CAS  PubMed  Google Scholar 

  14. Thomas GT, Dembo AJ. Is there a role for adjuvant pelvic radiotherapy after radical hysterectomy in early stage cervical cancer? Int J Gynecol Cancer. 1991;1:1–8.

    Article  Google Scholar 

  15. Uno T, Isobe K, Yamamoto S, et al. Postoperative radiation therapy for carcinoma of the uterine cervix. Radiat Med. 2006;24:91–7.

    Article  PubMed  Google Scholar 

  16. Monk BJ, Wang J, Im S, et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a gynecologic oncology group/southwest oncology group/radiation therapy oncology group trial. Gynecol Oncol. 2005;96:721–8.

    Article  PubMed  Google Scholar 

  17. Uno T, Ito H, Isobe K, et al. Postoperative pelvic radiotherapy for cervical cancer patients with positive parametrial invasion. Gynecol Oncol. 2005;96:335–40.

    Article  PubMed  Google Scholar 

  18. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. Gynecol Oncol. 1999;73:177–83.

    Article  CAS  PubMed  Google Scholar 

  19. Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 1990;38:352–7.

    Article  CAS  PubMed  Google Scholar 

  20. Putte G, Lie AK, Vach W, et al. Risk grouping in stage IB squamous cell cervical carcinoma. Gynecol Oncol. 2005;99:106–12.

    Article  PubMed  Google Scholar 

  21. Ryu SY, Kim MH, Nam BH, et al. Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean gynecologic oncology group study. Br J Cancer. 2014;110:278–85.

    Article  CAS  PubMed  Google Scholar 

  22. Rogers L, Ss S, Luesley D, et al. Radiotherapy and chemoradiation after surgery for early cervical cancer. Cochrane Database Syst Rev. 2012;5:CD007583. https://doi.org/10.1002/14651858. http://www.ncbi.nlm.nih.gov/pubmed/22592722.

    Article  CAS  PubMed  Google Scholar 

  23. Ryu SY, Park SI, Nam BH, et al. Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors? Int J Radiat Oncol Biol Phys. 2011;79:794–9.

    Article  PubMed  Google Scholar 

  24. Adegoke O, Kulasingam A, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Women's Health. 2012;21:1031–7.

    Article  Google Scholar 

  25. Eifel PJ, Burke TW, Morris M, et al. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol. 1995;59:38–44.

    Article  CAS  PubMed  Google Scholar 

  26. Lai C, Hsueh S, Hog JH, et al. Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery? Int J Gynecol Cancer. 1999;9:28–36.

    Article  PubMed  Google Scholar 

  27. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New Engl J Med. 1999;340:1144–53.

    Article  CAS  PubMed  Google Scholar 

  28. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. New Engl J Med. 1999;340:1137–43.

    Article  CAS  PubMed  Google Scholar 

  29. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. New Engl J Med. 1999;340:1154–61.

    Article  CAS  PubMed  Google Scholar 

  30. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a gynecologic oncology group and southwest oncology group study. J Clin Oncol. 1999;17:1339–148.

    Article  CAS  PubMed  Google Scholar 

  31. Takekuma M, Kasamatsu Y, Kado N, et al. Reconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancer. J Obstet Gynaecol Res. 2015;41:1638–43.

    Article  CAS  PubMed  Google Scholar 

  32. Takekuma M, Kasamatsu Y, Kado N, et al. Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy. Int J Clin Oncol. 2016;21:741–7.

    Article  CAS  PubMed  Google Scholar 

  33. Takeshima N, Umayahara K, Fujiwara K, et al. Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer. Gynecol Oncol. 2006;103:618–22.

    Article  CAS  PubMed  Google Scholar 

  34. Hosaka M, WatariH KT, et al. Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients with cervical cancer who underwent radical hysterectomy and systematic lymphadenectomy. J Surg Oncol. 2012;105:612–6.

    Article  CAS  PubMed  Google Scholar 

  35. Matoda MM, Takeshima N, Michimae H, et al. Postoperative chemotherapy for node-positive cervical cancer: results of a multicenter phase II trial (JGOG1067). Gynecol Oncol. 2018;149:513–9.

    Article  CAS  PubMed  Google Scholar 

  36. Takekuma M, Shimokawa M, Nishio S, et al. Phase II study of adjuvant chemotherapy with paclitaxel and nedaplatin for uterine cervical cancer with lymph node metastasis. Cancer Sci. 2018;109:1602–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Matsuo K, Nusbaum DJ, Matsuzaki S, et al. Utilization and outcomes of adjuvant systemic chemotherapy alone in high risk, early stage cervical cancer in the United States. Int J Gynecol Cancer. 2021;31:991–1000.

    Article  PubMed  Google Scholar 

  38. Furusawa A, Takekuma M, Mori K, et al. A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese gynecologic oncology group study (JGOG1082). Int J Gynecol Cancer. 2021;31:623–6.

    Article  PubMed  Google Scholar 

  39. Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic factors: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65:169–76.

    Article  PubMed  Google Scholar 

  40. Zunino S, Rosto O, Lucino S, et al. Anatomic study of the pelvis in carcinoma of the uterine cervix as related to the box technique. Int J Radiat Oncol Biol Phys. 1999;44:53–9.

    Article  CAS  PubMed  Google Scholar 

  41. Cibula D, Abu-Rustum NR, Fischerova D, et al. Surgical treatment of “intermediate risk” lymph node negative cervical cancer patients without adjuvant radiotherapy- a retrospective cohort study and review of the literature. Gynecol Oncol. 2018;151:438–43.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Cao L, Wen H, Feng Z, et al. Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer. Int J Gynecol Cancer. 2021;31:52–8.

    Article  PubMed  Google Scholar 

  43. Cibula D, Borcinova M, Kocian R, et al. CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo)radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16). Int J Gynecol Cancer. 2022;32:1327. https://doi.org/10.1136/ijgc-2022-003918.

    Article  Google Scholar 

  44. Ho CM, Chien TY, Huang SH, et al. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecol Oncol. 2004;93:458–64.

    Article  PubMed  Google Scholar 

  45. Rosa DD, Medeiros LR, Edelweiss ML, et al. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev. 2012;5:CD007583.

    Google Scholar 

  46. Kim K, Kang SB, Chung HH, et al. Comparison of chemoradiation with radiation as postoperative adjuvant therapy in cervical cancer patients with intermediate-risk factors. Eur J Surg Oncol. 2009;35:192–6.

    Article  CAS  PubMed  Google Scholar 

  47. Chen MF, Tseng CJ, Tseng CC, et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1438–44.

    Article  CAS  PubMed  Google Scholar 

  48. Mitsuhashi A, Uno T, Usui H, et al. Postoperative concurrent daily low-dose cisplatin-based chemoradiation improves the prognosis of patients with pathologic T2b or N1 cervical cancer. Anticancer Res. 2010;30:2341–6.

    CAS  PubMed  Google Scholar 

  49. Heinzelmann F, Henke G, von Grafensten M, et al. Adjuvant radiochemotherapy in patients with locally advanced high-risk cervical cancer. Strahlenther Onkol. 2012;18:568–75.

    Article  Google Scholar 

  50. Pu J, Qin SS, Ding JX, et al. A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery. J Cancer Res Clin Oncol. 2013;139:703–8.

    Article  CAS  PubMed  Google Scholar 

  51. Isohashi F, Yoshioka Y, Mabuchi S, et al. Intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: comparison of outcome, complications, and dose-volume histogram parameters. Radiat Oncol. 2015;10:180. https://doi.org/10.1186/s13014-015-0486-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Barter JF, Soong SJ, Shingleton HM, et al. Complications of combined radical hysterectomy-postoperative radiation therapy in women with early stage cervical cancer. Gynecol Oncol. 1989;32:292–6.

    Article  CAS  PubMed  Google Scholar 

  53. Ohba Y, Todo Y, Kobayashi N, et al. Risk factors for lower-limb lymphedema after surgery for cervical cancer. Int J Clin Oncol. 2011;16:238–43.

    Article  PubMed  Google Scholar 

  54. Oda Y, Todo Y, Hanley S, et al. Risk factors for persistent low bladder compliance after radical hysterectomy. Int J Clin Oncol. 2011;21:167–72.

    Google Scholar 

  55. Folkert MR, Shin KK, Abu-Rustum NR, et al. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer. Gynecol Oncol. 2013;128:288–93.

    Article  CAS  PubMed  Google Scholar 

  56. Jhingran A, Winter K, Portelance L, et al. A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418. Int J Radiat Oncol Biol Phys. 2012;84:e23–8.

    Article  PubMed  Google Scholar 

  57. Klopp AH, Moughan J, Portelance L, et al. Hematologic toxicity in RTOG0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys. 2013;86:83–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Shizuoka Cancer Center, Shizuoka, Japan

    Munetaka Takekuma

Authors
  1. Munetaka Takekuma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Munetaka Takekuma .

Editor information

Editors and Affiliations

  1. Akasaka Sanno Medical Center, International University of Health and Welfare Graduate School, Tokyo, Japan

    Daisuke Aoki

Rights and permissions

Reprints and permissions

Copyright information

© 2024 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Takekuma, M. (2024). Postoperative Adjuvant Therapy for Cervical Cancer. In: Aoki, D. (eds) Recent Topics on Prevention, Diagnosis, and Clinical Management of Cervical Cancer. Comprehensive Gynecology and Obstetrics. Springer, Singapore. https://doi.org/10.1007/978-981-99-9396-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-9396-3_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-9395-6

  • Online ISBN: 978-981-99-9396-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation